首页> 外文期刊>Gastroenterology research and practice >Clinical Application of CT-Guided Percutaneous Microwave Ablation for the Treatment of Lung Metastasis from Colorectal Cancer
【24h】

Clinical Application of CT-Guided Percutaneous Microwave Ablation for the Treatment of Lung Metastasis from Colorectal Cancer

机译:CT引导经皮微波消融治疗结直肠癌肺转移的临床应用

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. The aim of our research is to explore the clinical efficacy and safety of CT-guided percutaneous microwave ablation (MWA) for the treatment of lung metastasis from colorectal cancer. Materials and Methods. CT-guided percutaneous MWA was performed in 22 patients (male 14, female 8, mean age: 56.05?±?12.32 years) with a total of 36 lung metastatic lesions from colorectal cancer between February 2014 and May 2017. Clinical data were retrospectively analyzed with respect to the efficacy, safety, and outcome. Results. Of the 36 lesions, 34 lesions (94.4%) reduced obviously with small cavitations or fibrous stripes formed and had no evidence of recurrence during follow-up. The volume of the other 2 lesions demonstrated local progression after 6 months by follow-up CT. The primary complications included pneumothorax (28%), chest pain (21%), and fever (5%). These symptoms and signs were obviously relieved or disappeared after several-day conservative treatment. The mean follow-up of the patients was 25.54?±?12.58 months (range 2–41 months). The estimated progression-free survival rate was 94.4%. Conclusion. Our results demonstrate that CT-guided percutaneous MWA appears to be an effective, reliable, and minimally invasive method for the treatment of lung metastasis from colorectal cancer. This trial is registered with ChiCTR-ORC-17012904.
机译:客观的。我们的研究目的是探讨CT引导的经皮微波消融(MWA)的临床疗效和安全性,用于治疗从结肠直肠癌的肺转移。材料和方法。 CT引导的经皮MWA是在22名患者中进行的(男性14,女性8,平均年龄:56.05?±12.32岁),共有36例从2014年2月和2017年5月之间的结肠直肠癌肺转移性病变。临床数据被回顾性分析关于疗效,安全和结果。结果。在36个病变中,34个病变(94.4%)明显减少,具有小型空腔或纤维条纹,并且在随访期间没有复发的证据。通过随访CT,另外2个病变的体积显示6个月后局部进展。主要并发症包括气胸(28%),胸痛(21%)和发烧(5%)。在几天的保守治疗后,这些症状和迹象显然减轻或消失。患者的平均随访时间为25.54?±12.58个月(范围2-41个月)。估计的无进展生存率为94.4%。结论。我们的结果表明,CT引导的经皮MWA似乎是一种有效,可靠,可侵入性的血液直肠癌肺转移的侵入性方法。此试验在CHICTR-ORC-17012904注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号